December 18th 2025
Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.
Low-dose Rivaroxaban plus Aspirin Effective in CAD/PAD Regardless of Multimorbidity, Polypharmacy
July 15th 2021In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.